Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bankruptstock, you need to call them to participate in the REX Retail offer.
HL haven’t mentioned any REX offer? Should I have received an email from them?
There isn’t a hope in hell that nice will give full recommendation
They are just lining their own pockets before IP sold off or the company is taken private!!!!!
here’s the thing management only value the business at 1.5p per share. why would anyone else think the business is worth more. they have limped on from one raise to another and when this failed they went to the lender of last resort in riverfort .. this then destroyed the share price .. they have now gone back to the market for a **** or busy raise on 3 fronts when the share price is on its knees and leading to massive dilution.. all this while the business has produced almost no sales at all. and have not attempted to keep or reduce costs
the question is do you believe they are capable of getting the potential sales they suggest is available with in the time the capital raise will allow . there is definitely potential.. but it’s whether these executives can exploit this .. given what’s gone on for the last 3-4 years
Yes, You can apply for as many shares as you want...provided you have the funds! If you are with HL you can also apply for the REX offer.
Yes check your inbox or junk box
I have been offered 93124 shares for £1396.86. Can apply for more but not guaranteed through HL
Still no sign of open offer from Halifax, they are really slow :(
Just received an email from II about the open offer.
A great chance to average down further.
To those who were wondering about HL, I have now received the offer entitlement and instructions via their messaging service.
Note - that the application has to be done through the website. It cannot be done through the app.
Also, when the time comes, the shareholders voting that will be required will also be through the website.
HTH
Has anybody who is with HL had anything through yet regarding open offer?
All the eggs are in the NICE basket now.
Let’s see if the basket stays intact in July!
The share price is 70% down YTD and the market is about ti be flooded with 500million new shares
People have the right to be absolutely furious but in your copy pasted list you are making out like 250k revenue In 6 months is a big deal, that doesn't even cover 3 weeks of cash burn
NICE better pull their finger out.
Excellent post. Exactly as i see it also Eureka01. Hence why i have maxed out on the retail & open offer.
Well said that man Eureka01👍
There are some on here who can only see the downside of GDR. I am seeing statements like "Genedrive spend spend spend spend NO INCOME", "Shareholders should and must vote a firm No", "There is a reason why this 💩 is as good as worthless".
Yet there are many reasons to be positive.
Possible News Flow
AIHL: Additional go live sites in the UK
NHS specialist commissioning which is expected in April 2025
Change in NICE guidance from conditional to full.
Commercial progress in nine other countries across Europe and the Middle East where contracted distributors are in place and are currently in the in-county pilot phase.
Eventual regulatory approval in the USA via the FDA De novo submission process.
Stroke Test: NICE's final recommendation for the CYP2C19 test is expected on 10 July 2024.
Completion of the DEVOTE clinical study.
CE-IVD submission in H2 2024 with certification anticipated in early 2025.
Commercialization in the UK.
Commercialization within the EU.
Eventual FDA registration process for CYP2C19 to permit future sales in the USA
Sources of Revenue
The company is already making income: Revenues and other income in the six months to 31 December 2023 were £0.24 million.
The Board's internal assumptions of revenue growth forecast the Company transitioning to a positive EBITDA position in the second half the financial year ending 30 June 2026.
AIHL: The Company estimates that the total addressable UK market is up to £8.5 million per annum which is based on approximately 100,000 NICU admissions per annum and an estimated customer price per test of more than £80. The EU market is potentially another c.£46.75 million per annum, the U.S. market is c.£34 million and rest of World markets around £13.75 million.
The Group expects to drive revenues for the MT RNR1 test from additional go-live sites in the UK and abroad.
Stroke Test Kit: UK market is up to £8.5 million per annum, based on the assumption that there are over 100,000 strokes per annum and an estimated customer price per test of approximately £100. The EU market is estimated to be c.£93.5 million, the U.S. market is c.£67.6 million and rest of the world markets approximately £51 million. The company will start sales and marketing activity in the UK for the CYP2C19 test will start as well as pursuing research use only sales outside of the UK.
Yes, there are the risks: Uncertainty of regulatory approvals, failure of regulatory trials and so on. But the biggest risk IMO would be the failure to achieve the £6 million fund raise. For me the outlook for the company is, on balance, positive and I shall ignore the doom mongers and will be supporting the fund raise.
🥱
Genedrive spend spend spend spend NO INCOME!!!!!
*reading
6-8 million raised easily. Onwards into commercialisation. No looking back. Will be 10/15p come August / September. Or even sooner. Take up the offer. Switch off. Come back in 4/5 months and avoid ready the sh**e posted on here.
If this Placing goes ahead, the SP will most definitely fall to a penny or even worse. Shareholders should and must vote a firm No.
Heavy buys coming in.....🤣🤣🤣🤣🤣
And he certainly wouldn't have done a Placing at 50% discount.